Schering Rebetron
Executive Summary
Arbitration panel denies Biogen's claims to increased royalties on Rebetron. Biogen maintained increased royalties should be paid under a 1979 licensing agreement for Biogen's alpha interferon patents, because the drug qualified as a combination product, containing Intron A and Rebetol. Biogen indicated that it will continue to receive royalties on Rebetron "in the form of royalties on Intron A"